Art

J-GLOBAL ID：201402213436245268   Reference number：14A1342830

Combination of hemoglobin, alkaline phosphatase, and age predicts optimal docetaxel regimen for patients with castration-resistant prostate cancer

ヘモグロビンとアルカリ性ホスファターゼと年齢の組合わせは去勢抵抗性前立腺癌患者の最適ドセタキセル処方を予測する

Author (13)： MATSUYAMA Hideyasu (Yamaguchi Univ. Graduate School of Medicine, Yamaguchi, JPN) ,  SHIMABUKURO Tomoyuki (Ube Ind. Central Hospital, Ube, JPN) ,  HARA Isao (Wakayama Medical Univ., Wakayama, JPN) ,  KOHJIMOTO Yasuo (Wakayama Medical Univ., Wakayama, JPN) ,  SUZUKI Kazuhiro (Gunma Univ. Graduate School of Medicine, Maebashi, JPN) ,  KOIKE Hidekazu (Gunma Univ. Graduate School of Medicine, Maebashi, JPN) ,  UEMURA Hirotsugu (Kinki Univ. Fac. Medicine, Osakayama, JPN) ,  HAYASHI Taiji (Kinki Univ. Fac. Medicine, Osakayama, JPN) ,  UENO Munehisa (Saitama Medical Univ. International Medical Center, Hidaka, JPN) ,  KODAIRA Kiichiro (Saitama Medical Univ. International Medical Center, Hidaka, JPN) ,  TOMITA Yoshihiko (Yamagata Univ. Fac. Medicine, Yamagata, JPN) ,  SAKURAI Toshihiko (Yamagata Univ. Fac. Medicine, Yamagata, JPN) ,  SHIMIZU Nobuaki (Gunma Prefectural Cancer Center, Ota, JPN)
Material： International Journal of Clinical Oncology  (Int J Clin Oncol)
Volume： 19  Issue： 5  Page： 946-954  Publication year： Oct. 2014 
JST Material Number： L3966A  ISSN： 1341-9625  Document type： Article
Article type： 原著論文  Country of issue： Germany, Federal Republic of (DEU)  Language： ENGLISH (EN)

Thesaurus term： human(primates) ,...
Semi thesaurus term： リスクモデル ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=14A1342830&from=J-GLOBAL&jstjournalNo=L3966A") }}

JST classification (3)： Urogenital tumors(=neoplasms)  (GM04000S) ,  Clinical application of antitumor(=antineoplastic)drugs  (GW16020L) ,  Drug therapy(=pharmacotherapy)for tumors  (GE03032C)

Substance index (1)： Docetaxel

Reference (23)：

• Ohshima A, Kuroishi T, Tajima K (2004) Cancer statistics white paper disease/death/prognosis 2004. Shinoharashinsha, Tokyo, pp 201-217, 220-234
• Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502-1512
• Berthold DR, Pond GR, Soban F et al (2008) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 26:242-245
• Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513-1520
• de Bono JS, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005

Terms in the title (9)： ヘモグロビン ,  アルカリ性ホスファターゼ ,  年齢 ,  組合わせ ,  去勢抵抗性前立腺癌 ,  患者 ,  ドセタキセル ,  処方 ,  予測